NR4A1 and ductal breast carcinoma in situ: In several countries, national guidelines recommend hormone receptor status assessment since adjuvant treatment with tamoxifen or aromatase inhibitors in hormone receptor-positive DCIS reduces both the ipsilateral recurrence risk and the contralateral breast cancer risk [3–5].